Holen Sie sich die Stockscreener-App
12.92
10.28%
-1.48
Handel nachbörslich:
12.92
Schlusskurs vom Vortag:
$14.40
Offen:
$14.41
24-Stunden-Volumen:
315.41K
Relative Volume:
0.87
Marktkapitalisierung:
$434.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-8.254
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
-9.46%
1M Leistung:
+3.03%
6M Leistung:
+19.85%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.76
$14.95
1-Wochen-Bereich:
$12.76
$15.19
52-Wochen-Spanne:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
12.92 | 489.46M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity - MarketScreener
MBX Biosciences Begins Phase 1 Trial for Obesity Drug - TipRanks
MBX Biosciences begins phase 1 trial of obesity treatment candidate - Investing.com
First-Ever Monthly GLP-1/GIP Obesity Drug Enters Clinical Trials: MBX Biosciences' Novel Treatment Begins Testing - Stock Titan
Is MBX Biosciences Inc. forming a reversal patternPortfolio Gains Summary & Reliable Price Breakout Alerts - Newser
How to escape a deep drawdown in MBX Biosciences Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Momentum Traders Eye MBX Biosciences Inc. for Quick BouncePortfolio Profit Report & Risk Managed Trade Strategies - beatles.ru
Will MBX Biosciences Inc. rebound enough to break evenJuly 2025 Fed Impact & Low Drawdown Investment Ideas - Newser
Identifying reversal signals in MBX Biosciences Inc.Weekly Investment Report & Fast Momentum Entry Tips - Newser
How hedge fund analytics apply to MBX Biosciences Inc. stockJuly 2025 Technicals & AI Driven Price Forecasts - Newser
Risk adjusted return profile for MBX Biosciences Inc. analyzedDollar Strength & Community Driven Trade Alerts - Newser
Is MBX Biosciences Inc. still worth holding after the dipGold Moves & Fast Entry Momentum Trade Alerts - Newser
Does MBX Biosciences Inc. meet Warren Buffett’s criteria2025 Macro Impact & Short-Term High Return Ideas - khodrobank.com
Technical analysis overview for MBX Biosciences Inc. stockMarket Activity Report & Advanced Swing Trade Entry Plans - Newser
How does MBX Biosciences Inc. compare to its peersLayoff News & AI Driven Stock Price Forecasts - khodrobank.com
Smart tools for monitoring MBX Biosciences Inc.’s price action2025 Market Trends & Detailed Earnings Play Strategies - Newser
What technical models suggest about MBX Biosciences Inc.’s comeback2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Why MBX Biosciences Inc. is moving todayEarnings Growth Report & Low Drawdown Investment Ideas - Newser
Buyout Rumor: Is MBX Biosciences Inc. trading at a discountJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - khodrobank.com
What is MBX Biosciences Inc.’s book value per share2025 Dividend Review & Daily Profit Maximizing Tips - khodrobank.com
What’s the recovery path for long term holders of MBX Biosciences Inc.CEO Change & Precise Entry and Exit Recommendations - Newser
Using portfolio simulators with MBX Biosciences Inc. includedJuly 2025 Highlights & Fast Entry High Yield Tips - Newser
MBX Biosciences Inc. stock daily chart insightsJuly 2025 Breakouts & Free Community Consensus Stock Picks - Newser
What’s the beta of MBX Biosciences Inc. stockPortfolio Return Summary & Daily Profit Maximizing Tips - khodrobank.com
MBX Awaits Value-Creating Milestones, With Phase II Hypoparathyroidism Data Due Any Day - insights.citeline.com
Does MBX Biosciences Inc. show high probability of reboundWeekly Earnings Recap & Community Verified Trade Signals - Newser
What high frequency data says about MBX Biosciences Inc.2025 Support & Resistance & Stock Market Timing Techniques - Newser
Evaluating MBX Biosciences Inc. with trendline analysis2025 Market Overview & Long-Term Growth Stock Strategies - Newser
MBX Biosciences Inc. stock retracement – recovery analysis2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
MBX Biosciences Inc. stock prediction for this weekMarket Activity Recap & Long-Term Growth Portfolio Plans - Newser
How to recover losses in MBX Biosciences Inc. stockJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
Volatility clustering patterns for MBX Biosciences Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - Newser
Using economic indicators to assess MBX Biosciences Inc. potentialWatch List & Real-Time Market Sentiment Reports - Newser
Applying Wyckoff theory to MBX Biosciences Inc. stockTrade Ideas & Scalable Portfolio Growth Methods - Newser
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mbx Biosciences Inc-Aktie (MBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| GORDON CARL L | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| ORBIMED ADVISORS LLC | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| ORBIMED ADVISORS LLC | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| Hawryluk P. Kent | President & CEO |
Feb 04 '25 |
Buy |
10.69 |
50,000 |
534,500 |
448,277 |
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):